Literature DB >> 8419133

Isoelectric charge of recombinant human follicle-stimulating hormone isoforms determines receptor affinity and in vitro bioactivity.

A Cerpa-Poljak1, L A Bishop, Y J Hort, C K Chin, R DeKroon, S M Mahler, G M Smith, M C Stuart, P R Schofield.   

Abstract

Recombinant human FSH (rhFSH) was obtained by expressing the human FSH alpha- and beta-subunit complementary DNAs in the chinese hamster ovary cell line. Isoforms of rhFSH were resolved into specific isoelectric (pI) fractions by chromatofocusing. rhFSH isoforms ranged from pI 3.0-5.5 with a modal value of pI 4.2. Analysis of the biological activity of specific pI isoforms of rhFSH was undertaken using both the rat granulosa cell aromatase (in vitro) bioassay and a RRA. More acidic isoforms (e.g. pI 3.5) showed significantly lower affinity (P < 0.05) for rat testicular FSH receptors than did the less acidic isoforms (e.g. pI 4.8). Consistent with the receptor binding affinity data, the more acidic fractions resulted in significantly less activation (P < 0.05) of rat granulosa cell aromatase activity, as measured by estrogen production, than did the less acidic isoforms. The observed bioactivities and their correlation with the pI values of the rhFSH isoforms are consistent with observations of differing bioactivities seen in both pituitary and urinary FSH isoforms. These results demonstrate that rhFSH, made in the chinese hamster ovary cell line, is both biologically active and has isoform profiles, and presumably carbohydrate structures, that closely resemble those seen in natural hFSH.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419133     DOI: 10.1210/endo.132.1.8419133

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Receptor binding activity and in vitro biological activity of the human FSH charge isoforms as disclosed by heterologous and homologous assay systems: implications for the structure-function relationship of the FSH variants.

Authors:  E Zambrano; T Zariñán; A Olivares; J Barrios-de-Tomasi; A Ulloa-Aguirre
Journal:  Endocrine       Date:  1999-04       Impact factor: 3.633

2.  Sequential (hFSH + recFSH) vs homogenous (hFSH or recFSH alone) stimulation: clinical and biochemical (cumulus cell gene expression) aspects.

Authors:  Timur Gurgan; Debbie Montjean; Aygul Demirol; Yves J R Menezo
Journal:  J Assist Reprod Genet       Date:  2014-03-18       Impact factor: 3.412

Review 3.  Gene expression in Mammalian cells and its applications.

Authors:  Kishwar Hayat Khan
Journal:  Adv Pharm Bull       Date:  2013-08-20

4.  Biological activity and metabolic clearance of recombinant human follicle stimulating hormone produced in Sp2/0 myeloma cells.

Authors:  C K Chin; P R Schofield; D M Robertson; P P Gray; W Chotigeat; S M Mahler
Journal:  Cytotechnology       Date:  1996-06       Impact factor: 2.058

5.  Superovulation before IVF by recombinant versus urinary human FSH (combined with a long GnRH analog protocol): a comparative study.

Authors:  B Fisch; O M Avrech; H Pinkas; A Neri; O Rufas; J Ovadia; E Loumaye
Journal:  J Assist Reprod Genet       Date:  1995-01       Impact factor: 3.412

6.  Pressuromodulation at the cell membrane as the basis for small molecule hormone and peptide regulation of cellular and nuclear function.

Authors:  Hemant Sarin
Journal:  J Transl Med       Date:  2015-11-26       Impact factor: 5.531

7.  Purification Process of a Recombinant Human Follicle Stimulating Hormone Biosimilar (Primapur®) to Yield a Pharmaceutical Product with High Batch-to-Batch Consistency.

Authors:  Maria Sinegubova; Ivan Vorobiev; Anatoly Klishin; Dmitry Eremin; Nadezhda Orlova; Natalya Orlova; Mikhail Polzikov
Journal:  Pharmaceutics       Date:  2022-01-01       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.